Literature DB >> 9168885

Identification of regions in HIV-1 Nef required for efficient downregulation of cell surface CD4.

J Hua1, W Blair, R Truant, B R Cullen.   

Abstract

Downregulation of cell surface CD4 is a characteristic property of all lentiviral Nef proteins. We have used mutational analysis to define regions within HIV-1 Nef that are critical for this biological activity. Two discontinuous regions in Nef, extending approximately from residues 96 to 144 and from residues 175 to 186, are reported to be essential for efficient CD4 downregulation. Interestingly, these sequences coincide with two conserved regions of the Nef protein that are juxtaposed to form a single surface on the known structure of Nef. A third, more amino terminal conserved region in Nef, previously reported to be important for Nef enhancement of virion infectivity, was found to be largely dispensable for CD4 downregulation. These data raise the possibility that Nef may contain two structurally distinct functional domains, only one of which contributes to the CD4 downregulation phenotype.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9168885     DOI: 10.1006/viro.1997.8517

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  22 in total

1.  The human Tap protein is a nuclear mRNA export factor that contains novel RNA-binding and nucleocytoplasmic transport sequences.

Authors:  Y Kang; B R Cullen
Journal:  Genes Dev       Date:  1999-05-01       Impact factor: 11.361

2.  Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity.

Authors:  H M Craig; M W Pandori; J C Guatelli
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

Review 3.  Using death to one's advantage: HIV modulation of apoptosis.

Authors:  T M Ross
Journal:  Leukemia       Date:  2001-03       Impact factor: 11.528

4.  Modeling the evolution of SIV sooty mangabey progenitor virus towards HIV-2 using humanized mice.

Authors:  Kimberly Schmitt; Dipu Mohan Kumar; James Curlin; Leila Remling-Mulder; Mark Stenglein; Shelby O'Connor; Preston Marx; Ramesh Akkina
Journal:  Virology       Date:  2017-07-24       Impact factor: 3.616

5.  Genetic and functional diversity of human immunodeficiency virus type 1 subtype B Nef primary isolates.

Authors:  J L Foster; R P Molina; T Luo; V K Arora; Y Huang; D D Ho; J V Garcia
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

6.  Detection of human immunodeficiency virus type 1 Nef and CD4 physical interaction in living human cells by using bioluminescence resonance energy transfer.

Authors:  David Cluet; Christophe Bertsch; Christian Beyer; Liliane Gloeckler; Mathieu Erhardt; Jean-Pierre Gut; Jean-Luc Galzi; Anne-Marie Aubertin
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

7.  Consequences of HLA-B*13-Associated Escape Mutations on HIV-1 Replication and Nef Function.

Authors:  Aniqa Shahid; Alex Olvera; Gursev Anmole; Xiaomei T Kuang; Laura A Cotton; Montserrat Plana; Christian Brander; Mark A Brockman; Zabrina L Brumme
Journal:  J Virol       Date:  2015-09-09       Impact factor: 5.103

8.  Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.

Authors:  Roger G Ptak; Brian G Gentry; Tracy L Hartman; Karen M Watson; M Clayton Osterling; Robert W Buckheit; Leroy B Townsend; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

9.  Nef-induced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking.

Authors:  A Mangasarian; V Piguet; J K Wang; Y L Chen; D Trono
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 Nef protein targets CD4 to the multivesicular body pathway.

Authors:  Luis L P daSilva; Rachid Sougrat; Patricia V Burgos; Katy Janvier; Rafael Mattera; Juan S Bonifacino
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.